Unknown

Dataset Information

0

A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy.

ABSTRACT:

SUBMITTER: Liu Y 

PROVIDER: S-EPMC10958672 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy.

Liu Yingqiang Y   Tong Linjiang L   Zhang Mengge M   Zhang Qi Q   Liu Qiupei Q   Feng Fang F   Li Yan Y   Lai Mengzhen M   Tang Haotian H   Chen Yi Y   Geng Meiyu M   Duan Wenhu W   Ding Jian J   Xie Hua H  

Cancer communications (London, England) 20240209 3

Similar Datasets

Unknown Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
| S-EPMC6319306 | biostudies-literature
Unknown Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
| S-EPMC8906048 | biostudies-literature
Unknown Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
| S-EPMC9113929 | biostudies-literature
Unknown Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.
| S-EPMC8353919 | biostudies-literature
Unknown Targeting the immune microenvironment during immunotherapy for solid tumors.
| S-EPMC8632277 | biostudies-literature
Unknown Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.
| S-EPMC10085570 | biostudies-literature
Unknown PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
| S-EPMC5873884 | biostudies-literature
Unknown Immunotherapeutic target expression on breast tumors can be amplified by hormone receptor antagonism: a novel strategy for enhancing efficacy of targeted immunotherapy.
| S-EPMC5464807 | biostudies-literature
Unknown Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors.
| S-EPMC11705730 | biostudies-literature
Unknown The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
| S-EPMC7890731 | biostudies-literature